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Abstract
Background: Warfarin is used for the prevention and treatment of various thromboembolic
complications. It is an efficacious anticoagulant, but it has a narrow therapeutic range, and regular
monitoring is required to ensure therapeutic efficacy and at the same time avoid life-threatening
adverse events. The objective was to assess management and resource consumption associated
with patient monitoring episodes during warfarin treatment in primary health care in Sweden.
Methods: Delphi technique was used to systematically explore attitudes, demands and priorities,
and to collect informed judgements related to monitoring of warfarin treatment. Two separate
Delphi-panels were performed in three and two rounds, respectively, one concerning tests taken
in primary health care centres, involving 34 GPs and 10 registered nurses, and one concerning tests
taken in patients' homes, involving 49 district nurses.
Results: In the primary health care panel 10 of the 34 GPs regularly collaborated with a registered
nurse. Average time for one monitoring episode was estimated to 10.1 minutes for a GP and 21.4
minutes for a nurse, when a nurse assisted a doctor. The average time for monitoring was 17.6
minutes for a GP when not assisted by a nurse. Considering all the monitoring episodes, 11.6% of
patient blood samples were taken in the individual patient's home. Average time for such a
monitoring episode was estimated to 88.2 minutes. Of all the visits, 8.2% were performed in vain
and took on average 44.6 minutes. In both studies, approximately 20 different elements of work
concerning management of patients during warfarin treatment were identified.
Conclusion: Monitoring of patients during treatment with warfarin in primary health care in
Sweden involves many elements of work, and demands large resources, especially when tests are
taken in the patient's home.
Background
The prevalence of patients on anticoagulant (AC) treat-
ment in Sweden has been estimated to be between 0.75
and 0.88% (age adjusted) in a primary health care (PHC)
setting [1,2]. Oral ACs, i.e. vitamin K-antagonists, are used
for the prevention and treatment of various thromboem-
bolic complications. Their efficacy has been demonstrated
in a broad range of indications. These include the preven-
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tion of venous thromboembolism including pulmonary
embolism, thrombosis on heart valve prostheses, and the
prevention of stroke in chronic atrial fibrillation (CAF) [3-
5]. Furthermore, vitamin K-antagonists have been demon-
strated to be effective as secondary prophylaxis after myo-
cardial infarction [6].
The standard oral AC in Sweden is warfarin. It is an effica-
cious anticoagulant, but it has a narrow therapeutic range,
and interacts with a number of common drugs as well as
with food and alcohol. If under-coagulated the patient is
at risk of a thromboembolic event, while if over-coagu-
lated there is a risk of bleeding complications. Therefore,
patients on such treatment require regular monitoring of
International Normalized Ratio (INR) values, in order to
ensure therapeutic efficacy and at the same time avoid life-
threatening adverse events. In Sweden such monitoring
episodes are either managed by hospital anticoagulation
clinics, in PHC, or in the patient's home.
The frequency of INR monitoring visits has been shown to
be considerable for patients already established on warfa-
rin treatment and managed in PHC in Sweden [1]. The
burden on the health care sector to manage these patients
is sizeable, as the number of patients requiring such mon-
itoring episodes is large and each patient demands fre-
quent monitoring. Furthermore, each monitoring episode
is likely to be resource consuming, as a number of various
elements of work are involved and meticulous manage-
ment is critical for safety reasons. Health care resources are
scarce and therefore elements of work for various aspects
of health care should be continuously scrutinized. Thus a
basis can be created for decisions on the allocation of
health care resources to ensure that they are efficiently
used. To our knowledge the association of resource con-
sumption with INR monitoring episodes of patients dur-
ing warfarin treatment in PHC has not previously been
studied.
The objective of this study was to assess the management
and resource consumption that is associated with INR
monitoring episodes in patients during warfarin treat-
ment, in PHC, in Sweden.
Methods
The Delphi technique is a well-known method to system-
atically explore attitudes, demands and priorities of
groups of experts [7-11]. The experts are usually selected
to reflect current knowledge and perceptions in the field
under consideration. The Delphi technique is based on a
series of stages or iterations, where informed judgements
on specific issues are collected from experts. The experts
respond individually and anonymously to questions, to
avoid influence of contextual factors such as personal
characteristics, seniority and experience. Thereby, honest
opinion free from peer group pressure is encouraged. The
answers from all respondents in round one are put
together and the respondents given feedback. In the fol-
lowing round the individual respondent has the opportu-
nity to change his/her response. The depth of knowledge
therefore increases among the respondents. Delphi-pan-
els have commonly been used to build and measure con-
sensus. However, the design may vary with the objective
of the study, and one option is to canvass the relative
importance or desirability of specific items by rank or by
attitude statements according to ordinal scales, such as the
Likert Scale [12,13].
Two separate Delphi-panels were performed. One con-
cerned tests taken at a PHC centre (panel I), and the other
concerned tests taken in the patient's home (panel II).
Panel I included members randomly selected from gen-
eral practitioners (GPs) and nurses in PHC in Stockholm
County Council, and panel II included district nurses
throughout Sweden. Navigare Medical Marketing
Research AB, a medical research company, performed all
contacts and interviews with respondents. A project group
was nominated to develop the questionnaires and to
assess the answers from each round. This group com-
prised one representative from the medical research com-
pany, one from AstraZeneca Sverige and two from the
Center for Family Medicine, Karolinska Institutet, Stock-
holm. The identities of the panel members were not dis-
closed to the members of the project group.
The panel members were asked to i) identify elements of
work associated with INR monitoring; indicate (ii) the
time required to carry out each individual element of
work; and (iii) the frequency by which they normally
occur in a standard INR monitoring episode.
Information from previous rounds was fed back to the
individual respondents to encourage a thorough reassess-
ment of the individual answer. Hence the respondents
were repeatedly prompted to assess whether the time they
had indicated for the individual work processes added up
to a reasonable estimate of time.
The frequency with which individual items of the work
processes normally occurred was measured by a Likert
Scale, where 0 is "never" and 10 is "always".
INR tests taken at a PHC centre (panel I)
The objective of panel I was to assess resource consump-
tion associated with INR monitoring episodes in patients
during warfarin treatment when the INR test was taken at
a PHC centre.
A random sample of 50 GPs from all PHC centres in
Stockholm County was invited to participate in the study.BMC Family Practice 2006, 7:67 http://www.biomedcentral.com/1471-2296/7/67
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Out of a total of 940 GPs and 174 PHC centres three GPs
were selected at each of the 50 PHC centres, one as the pri-
mary respondent, and two additional as stand-in if the
primary respondent should be impossible to reach or
decline to participate. Where the GP routinely worked
with a registered nurse in managing warfarin patients this
nurse was invited to also participate in the study. The cri-
terion for inclusion was management of five or more
patients on warfarin treatment.
This Delphi-panel was performed in three rounds. The
first and second rounds were accomplished by telephone
interviews and the third round by a postal questionnaire.
The GPs participated in all three rounds while the nurses
only participated in the first and second round. In each of
the three rounds, the interviewer tried up to three times to
get in contact with the primary respondent by telephone.
If no contact was established, a reminder letter was sent to
the respondent. If contact still failed, the stand-in GP was
asked to participate. The PHC centre panel first round was
carried out in June 2003, the second round in September,
and the third and last round was in December 2003.
In the first round, the GP respondents were asked to iden-
tify various elements of work that were involved in INR
monitoring using an open-ended questionnaire. In each
element of work several sub-elements could be included.
For example, a GP could state when preparing for INR
monitoring that he both read up on the patient and went
through test results from a prior monitoring visit. It was
therefore possible for respondents to give more than one
answer to each element of work. The various elements of
work that were identified were divided into three sub-
groups: (i) preparations (ii) direct patient contact (iii) fol-
low-up. The responses were used to formulate more spe-
cific questions in the second round to gain a more
thorough understanding of the various elements of work
involved in the monitoring of warfarin. In the second
round, a list of all elements of work associated with INR
monitoring identified in the first round by the whole
panel was sent to the respondents prior to the new inter-
view. The respondents were then asked to estimate the
time required for executing the various elements of work
and how frequently each occurred. In the third round, the
respondents had the opportunity to revise their estimate
of time based on their initial estimate and the group
responses. The interviewer also totalled the time for the
various elements of work and prompted the respondents
as to whether this time appeared to be reasonable.
INR tests taken in the patient's home (panel II)
The objective of panel II was to assess the resource con-
sumption related to the INR monitoring episodes in
patients with CAF during warfarin treatment when the
INR test was taken in the patient's home.
A random sample of 106 district nurses from different
PHC centres in 34 regions were invited to take part in the
study. The sample of district nurses was stratified to
ensure participation from all over Sweden. Up to three
district nurses in each region were selected as primary
respondents, and one additional for each PHC centre as
stand-in if the primary respondent should be unable/
unwilling to participate. The inclusion criterion was that
each participating district nurse should manage no less
than five CAF patients. However, this criterion had to be
relaxed and redefined to "at least two patients", in order
to be able to find a sufficient number of district nurses eli-
gible to participate in the study. If both the primary and
stand-in district nurses selected from a specific PHC centre
failed to satisfy the inclusion criterion, the PHC centre was
excluded and replaced by another PHC centre.
This Delphi-panel was performed in two rounds. The first
round was accomplished by telephone interviews, and the
second round by a postal questionnaire. The interviewer
tried up to two times to contact the responder by tele-
phone. If the respondent was not possible to reach, a
reminder letter was sent out. If contact still failed, the
stand-in nurse was asked to participate. Both the first and
second round of the panels were carried out in December
2003.
The first round, a telephone interview, identified various
elements of work associated with INR monitoring in the
patient's home and canvassed the time required for each
element of work. The frequency with which each element
of work occurred and the distance to the patient's home
was also investigated. The work was divided into sections,
(i) preparations (ii) home visit and (iii) follow-up. In the
second round, accomplished by a postal questionnaire,
the question was reiterated and the respondents had the
opportunity to revise their estimate of time based on their
initial estimate and the group responses. After the comple-
tion of each section the respondent was asked if the total
time was reasonable.
When estimating the resource consumption per element
of work and responder, both the time required for carry-
ing out each specific element of work and the frequency
with which it occurred were taken into consideration.
Statistical considerations
In the statistical analyses, the frequency of occurrence of
each element of work was handled as quantitative, inter-
val scale data. Standard descriptive statistical calculations
were performed, such as arithmetical mean, minimum
and maximum. The uncertainty in the estimates was illus-
trated by a 95% confidence interval (CI).BMC Family Practice 2006, 7:67 http://www.biomedcentral.com/1471-2296/7/67
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Results
INR tests taken at a PHC centre (panel I)
Of the 50 GPs invited to the study, 35 actually participated
in the first round, 15 were primary respondents, 9 were
first stand-ins and 11 were second stand-ins. In the second
round one GP declined further participation and was
replaced by a stand-in. In the third round 34 of the 35 GPs
participated.
Ten of the 34 GPs collaborated with a registered nurse on
a routine basis in the management of patients attending a
PHC centre for INR monitoring. The remaining 24 GPs
either collaborated with laboratory staff or an assistant
nurse. A GP assisted by a nurse managed, on average, 40
patients with treatment on warfarin who visited the PHC
centre for INR monitoring and a nurse managed, on aver-
age, 88 patients. GPs without nurse assistance managed,
on average, 27 patients. Of all INR monitoring episodes,
11.6% of the blood samples were reported to be taken in
the individual patient's home.
Management of patients
The daily routines for managing warfarin patients varied
in and between the centres (Table 1). For GPs with an
assistant nurse, the blood sample was always taken, ana-
lyzed and administrated by laboratory staff. For GPs with-
out an assistant nurse, the blood sample in 74% of the
cases was regularly managed by laboratory staff and in the
remaining cases by nursing staff at the PCH centre. After
the blood sample had been taken the patient normally left
the PHC centre and the results of the INR test including
change of dosage, if any, was communicated at a later
time. The result of the test was always assessed by the GP
and usually communicated to the patient by the GP. How-
ever, where a nurse routinely assisted a GP, the nurse
shared this responsibility with the GP.
Time for INR monitoring
Total time for one INR monitoring episode for a GP
assisted by a nurse (n = 10) was, on average, 10.1 minutes
(CI 95% 5.4; 14.8), of which time for work preparation
was 2.6 minutes, time for direct patient contact 3.1 min-
utes and time for follow-up 4.4 minutes. Nurses (n = 10)
estimated total time for INR monitoring to 21.4 minutes
(CI 95% 11.0; 31.8), on average, where work of prepara-
tion was 4.5 minutes, 3.9 minutes direct patient contact
during the monitoring episode and 13.0 minutes for fol-
low-up. Total average time for a GP without nurse assistance
(n = 24) was 17.6 minutes (CI 95% 10.6; 24.6), of which
time for preparation was 4.4 minutes, direct patient con-
Table 1: Management of INR monitoring when tests are taken at PHC, (percentages).
How INR tests are communicated between 
laboratory and nursing staff
GPs without nurse n = 25 (%) GPs with nurse n = 10 (%) Nurses n = 10 (%)
Electronically 11 (44) 3 (30) 1 (10)
In writing ("Green Card")* 6 (24) 3 (30) 4 (40)
Verbally from nurse 3 (12) 3 (30) 3 (30)
Patient record (paper) 2 (8) 2 (20) 2 (20)
Location of patient at time when receiving test 
result
GPs without nurse n = 25 (%) GPs with nurse n = 10 (%) Nurses n = 10 (%)
At home 20 (80) 9 (90) 10 (100)
At PHC centre 10 (40) 4 (40) 3 (30)
Test result communicated to patient GPs without nurse n = 25 (%) GPs with nurse n = 10 (%) Nurses n = 10 (%)
Telephone 21 (84) 8 (80) 9 (90)
In writing 7 (28) 5 (50) 3 (30)
Verbally 6 (24) 4 (40) 4 (40)
In writing "Green Card" 5 (20) 1 (10) 1 (10)
Arranging new visit GPs without nurse n = 25 (%) GPs with nurse n = 10 (%) Nurses n = 10 (%)
In writing 9 (36) 1 (10) 2 (20)
Telephone patient 7 (28) 1 (10) 2 (20)
In writing "Green Card" 6 (24) 3 (30) 0 (0)
When prescription 4 (16) 2 (20) 4 (40)
When receiving test-results 5 (20) 2 (20) 1 (10)
*Green Card = a card held by the patient. N.B. Each respondent may score several items.BMC Family Practice 2006, 7:67 http://www.biomedcentral.com/1471-2296/7/67
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tact 6.1 minutes and time for follow-up 7.1 minutes. In
table 2, frequency used and time required per element of
work related to INR monitoring are given. Total average
time for all participating GPs (n = 34) was 15.4 minutes
(CI 95% 11.2; 19.6), of which time for work preparation
was 3.9 minutes, time for direct patient contact was 5.2
minutes and time for follow-up was 6.3 minutes. Results
of the estimates of time in the three rounds are shown in
table 3.
According to the GPs, the frequency with which patients
failed to turn up for their INR monitoring visits was 11%,
which the GPs estimated to consume 5.4 minutes (CI
95% 3.0; 7.8) of extra-work. Similarly, the nurses esti-
mated the frequency of non-appearance to 17% and their
assessment of the resulting extra-work was 4.9 minutes
(CI 95% 2.0;7.8).
INR tests taken in the patient's home (panel II)
Of the 106 district nurses, 50 nurses actually participated
in the first round, 52 did not meet the criteria related to
number of patient's managed, four nurses declined to par-
ticipate and one nurse was impossible to reach. The results
from the second round were based on 49 district nurses,
due to one drop-out. Each district nurse was responsible,
on average, for INR monitoring 4.9 CAF patients in their
homes.
The estimated time required for INR monitoring averaged
90.5 minutes in the first round and 88.2 minutes in the
Table 2: Frequency of activities and average time used per element of work when tests are taken at PHC centre (n = 34).
Preparations Average time used per element of work (minutes) Range
Take out patient's name 0.2 0.0–2.5
Take out patient's details 0.7 0.0–7.5
Read up on patient 1.0 0.0–15.0
Go through test results 0.6 0.0–5.0
Inform/discuss with nurse 0.3 0.0–5.0
Write lab. referral 0.2 0.0–3.0
Prepare patient information 0.3 0.0–10.0
Contact patient prior to checkup 0.7 0.0–13.5
Total time for preparations 3.9* 0.0–18.4
Direct patient contact Average time used per element of work (minutes) Range
Reception of patient prior to checkup 0.6 0.0–20.0
Collect patient from lab. 0.0 0.0–3.0
Personal discussion with patient 2.2 0.0–20.0
Inform patient of test results, new prescription 
and new appointment
1.3 0.0–15.0
Patient examination 1.1 0.0–30.0
Total direct patient contact 5.2 0.0–17.2
Follow-up Average time used per element of work (minutes) Range
Collect/take delivery of test results 0.3 0.0–5.0
Evaluate test results, new prescription 1.8 0.0–5.0
Complete and sign Waran form 1.0 0.0–5.0
Complete patient notes in computer 0.8 0.0–5.0
Complete patient notes in writing 0.2 0.0–3.0
Telephone patient 1.0 0.0–16.5
Write reply letter to patient 0.2 0.0–7.0
Write referral 0.2 0.0–3.0
Provide patient info to lab. 0.1 0.0–3.0
Provide patient info to nurse 0.6 0.0–5.0
Total time for follow-up 6.3* 0.0–29.7
Total time used for one monitoring episode 15.4 minutes 1.4–49.8
*the total is rounded off and thus does not correspond exactly with the sum of the individual items for follow-upBMC Family Practice 2006, 7:67 http://www.biomedcentral.com/1471-2296/7/67
Page 6 of 8
(page number not for citation purposes)
second round. The total time for one INR monitoring epi-
sode was, on average, 88.2 minutes (CI 95% 76.5; 99.9),
where time for work preparations was 23.9 minutes, direct
patient contact during the home visit 23.4 minutes, and
the time for follow-up after the home visit 40.8 minutes.
In table 4, frequency used and time required per element
of work related to INR monitoring is given.
Once a week, district nurses also made house calls to sup-
ply warfarin to patients' dose-dispending devices, and
about half the patients also required the nurses' help to
supply their medication. Some of these episodes
demanded two home visits for each INR monitoring epi-
sode, one for the blood sample and one to supply medi-
cation. Each home visit required the district nurses to
travel a mean distance of 13.7 km by car. About 8.2% of
the home visits were in vain as patients were not at home,
and the estimated mean extra time for such a fruitless visit
was 44.6 minutes (CI 95% 33.1; 56.1).
Discussion
In this study we assessed management and resource con-
sumption associated with INR monitoring episodes in
patients on warfarin treatment in PHC in Sweden. We
Table 4: Frequency of activities and average time used per element of work when tests are taken in the patient's home (n = 49).
Preparations Average time used per element of work (minutes) Range
Take out patient's details 2.1 0.0–7.0
Read up on patient 2.3 0.0–10.0
Go through test results 1.9 0.0–10.0
Prepare patient information 2.1 0.0–18.0
Contact patient prior to checkup 2.0 0.0–10.0
Travel to patient 13.7 1.5–45.0
Total time for preparations 23.9* 7.8–70.6
Home visit Average time used per element of work (minutes) Range
Discussion with patient on warfarin treatment incl. info to patient 4.8 0.0–42.0
Discussion with patient on social implications 10.5 3.0–30.0
Take blood sample 4.8 1.0–20.0
Label and pack blood sample 3.2 0.1–15.0
Total time for home visit 23.4* 7.1–76.5
Follow-up Average time used per element of work (minutes) Range
Travel from patient 14.1 1.5–50.0
Delivery of blood sample to lab. 7.8 0.0–60.0
Receive test results and new prescription 4.6 0.0–20.0
Complete patient notes in computer 3.6 0.0–10.0
Complete written patient notes 0.5 0.0–5.0
Telephone patient regarding new prescription etc. 1.3 0.0–5.0
Write reply letter to patient 0.0 0.0–1.5
Travel to and from patient again 4.8 0.0–36.0
Personally inform patient of new prescription etc. 1.6 0.0–7.5
Divide up the Waran in dosett 2.5 0.0–15.0
Total time for follow-up 40.8 8.0–146.1
Total time used for one monitoring episode 88.2 minutes 38.2–231.1
*the total is rounded off and thus does not correspond exactly with the sum of the individual items for preparations, and direct patient contact.
Table 3: Alteration in total time for INR monitoring between subsequent rounds, in minutes.
GPs without nurse, n = 25 GPs with nurse, n = 10 Nurses, n = 10
First round 19.0 13.0 17.0
Second round 19.3 12.1 21.4
Third round 17.6* 10.1 -
*One GP dropped out (n = 24).BMC Family Practice 2006, 7:67 http://www.biomedcentral.com/1471-2296/7/67
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found that such monitoring involves many elements of
work, and demands large health care resources, especially
when the INR test is taken in the patient's home. GPs,
assistant nurses, laboratory personnel and district nurses
take part in the monitoring most of the time, and as they
have different responsibilities of coordination, the ele-
ments of work add time to carry out an INR monitoring
episode. Another finding is that the time for follow-up
after the test is taken is considerable, especially in home
care.
PHC centres for the PHC panel (panel I) were solely
recruited from the Stockholm County Council, where
patients on warfarin are routinely managed in PHC. In
many other places in Sweden such patients are partly
cared for in anticoagulation clinics and partly in PHC. By
choosing Stockholm County Council as the study area,
confusion between different routines for management of
the patients was thus avoided. In the panel where INR
tests were taken in the patient's home (panel II) district
nurses from all over Sweden took part. In this setting the
distance to the caretaker is an important aspect, when
assessing the resource use in the management of the
patients, and a mixture of urban and rural areas was there-
fore felt to be necessary.
A limitation in our study is that it has only captured the
time spent by GPs and nurses dedicated to INR monitor-
ing visits, and district nurses. Further aspects of the work
carried out by other types of personnel, e.g. laboratory
staff and assistant nurses, have therefore not been
included. The results obtained are therefore to be regarded
as a conservative estimate of the resources required for car-
rying out INR monitoring episodes in PHC in Sweden.
The estimates of time decreased slightly in numerical
value when the questions were reiterated in successive
rounds. The respondents may have reflected over the
actual time they spent on various aspects of INR monitor-
ing episodes in between the rounds and therefore the final
estimate is likely to be the most valid one. In some cases
where GPs were nurse assisted there were discrepancies
between what the GPs and the nurses had stated concern-
ing different activities required when INR monitoring. It is
notable, therefore, that nurses managed on average three
times as many patients as doctors and it is therefore likely
that they assisted more than one doctor in the PHC. It is
also notable that the total time for a monitoring episode
was considerable longer when both the GP and the nurse
was involved.
In biomedical science, prospective, randomized, control-
led studies performed under experimental conditions or
trials are the generally accepted methodology for answer-
ing research questions within the health care sector. An
alternative method to answer the research question at
issue would have been to prospectively collect and meas-
ure resources required by observing the clinical daily rou-
tines in relation to INR monitoring of warfarin patients.
An apparent weakness of using such a method is, how-
ever, that persons being observed in carrying out their
work may intentionally or unintentionally change their
behaviour, which may influence the result. However, it is
doubtless that information based on attitudes and opin-
ions is afflicted with uncertainty. Information from expert
panels can, however, be gathered in a great number of
ways, from informal discussions among a group of experts
to standardised methods for gathering qualitative infor-
mation. The Delphi method is an example of such a
standardised method, and its methodology alleviates
some of the problems experienced by other kinds of
expert panel [14,15]. The process for carrying out the
study preserves the integrity of the individual respondent
without compromising the possibility to benefit from the
knowledge of the other panel members. The reiterative
procedure stimulates afterthought and gives the opportu-
nity to modify responses, which is likely to increase the
validity of the result of the study. We therefore believe the
result of our study represents a good estimate of the man-
agement of and resources used by INR monitoring epi-
sodes in PHC in Sweden. Our results may therefore be
used in further studies to explore the health care costs
related to monitoring of warfarin in PHC, including unit
costs of all individual costs items, and to address the eco-
nomic impact of warfarin treatment.
Conclusion
Monitoring of patients during treatment with warfarin in
PHC in Sweden involves many elements of work, and
demands large health care resources, especially when tests
are taken in the patient's home.
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